Alnylam hopes its ATTR-CM label will give Amvuttra an edgenews2025-03-21T18:50:43+00:00March 21st, 2025|Endpoints News|
The buildup to Chimerix’s $935M cash exit to Jazznews2025-03-21T16:28:15+00:00March 21st, 2025|Endpoints News|
FDA approves Novartis’ Fabhalta in C3 glomerulopathynews2025-03-21T15:38:57+00:00March 21st, 2025|Endpoints News|
AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneronnews2025-03-21T15:17:54+00:00March 21st, 2025|Endpoints News|
Johnson & Johnson earmarks $55B to boost US capacity news2025-03-21T11:16:37+00:00March 21st, 2025|Endpoints News|
FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBionews2025-03-20T21:40:37+00:00March 20th, 2025|Endpoints News|
ACIP meeting, delayed earlier this year, is reschedulednews2025-03-20T21:22:20+00:00March 20th, 2025|Endpoints News|
Akero exec calls MASH accelerated approval guidance ‘bizarre’news2025-03-20T19:41:09+00:00March 20th, 2025|Endpoints News|
Novo Nordisk lays out new structure for early R&D unitnews2025-03-20T18:44:17+00:00March 20th, 2025|Endpoints News|
